There are 2789 resources available
1150TiP - A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
Presenter: Kim Margolin
Session: ePoster Display
1152P - Real-world outcomes in resected stage IB-IIIA EGFR mutated NSCLC in Canada: Analysis from the POTENT study
Presenter: M. Kuruvilla
Session: ePoster Display
1113P - Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America
Presenter: Teodora Kolarova
Session: ePoster Display
1229P - Co-mutation of DNA damage repair (DDR) genes influence the efficiency of EGFR-TKIs in NSCLC patients harboring EGFR activating mutations
Presenter: Linlin Zhang
Session: ePoster Display
1116P - Well-differentiated neuroendocrine tumors of the kidney: Clinical characterics and treatment outcomes of a very rare disease
Presenter: Leonidas Apostolidis
Session: ePoster Display
1278P - SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+ advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
Presenter: Jifeng Feng
Session: ePoster Display
1279P - The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT)
Presenter: Alexander Meisel
Session: ePoster Display
1233P - EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation
Presenter: Yuxiang Wang
Session: ePoster Display